Stock analysts at HC Wainwright began coverage on shares of Aratana Therapeutics, Inc. (NASDAQ:PETX) in a research report issued on Friday. The firm set a “buy” rating and a $10.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 44.09% from the stock’s current price.
A number of other analysts have also recently weighed in on PETX. Jefferies Group LLC set a $9.00 price target on Aratana Therapeutics and gave the stock a “buy” rating in a research report on Thursday. Zacks Investment Research raised Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $7.75 price target for the company in a research report on Thursday, November 9th. ValuEngine cut Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. BidaskClub cut Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 8th. Finally, Lake Street Capital cut their price objective on Aratana Therapeutics from $15.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, August 25th. Two equities research analysts have rated the stock with a sell rating and six have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $8.75.
Shares of Aratana Therapeutics (PETX) opened at $6.94 on Friday. Aratana Therapeutics has a 12-month low of $4.97 and a 12-month high of $8.63. The company has a current ratio of 3.42, a quick ratio of 3.08 and a debt-to-equity ratio of 0.26.
Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.03. Aratana Therapeutics had a negative return on equity of 48.79% and a negative net margin of 358.55%. The company had revenue of $6.16 million during the quarter, compared to analysts’ expectations of $6.47 million. During the same quarter in the previous year, the firm earned ($0.38) earnings per share. The business’s quarterly revenue was up 1440.0% compared to the same quarter last year. equities research analysts anticipate that Aratana Therapeutics will post -1.04 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://ledgergazette.com/2017/11/17/aratana-therapeutics-inc-petx-research-coverage-started-at-hc-wainwright.html.
In related news, insider Peter Steven St sold 50,000 shares of the business’s stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $7.00, for a total transaction of $350,000.00. Following the transaction, the insider now directly owns 529,359 shares in the company, valued at $3,705,513. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ernst Heinen sold 10,000 shares of the business’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $6.25, for a total value of $62,500.00. Following the transaction, the insider now owns 130,994 shares in the company, valued at $818,712.50. The disclosure for this sale can be found here. Insiders have sold a total of 120,000 shares of company stock valued at $785,600 in the last three months. 5.20% of the stock is owned by insiders.
Institutional investors and hedge funds have recently modified their holdings of the stock. Janney Montgomery Scott LLC increased its stake in Aratana Therapeutics by 7.9% during the second quarter. Janney Montgomery Scott LLC now owns 16,400 shares of the biopharmaceutical company’s stock valued at $119,000 after acquiring an additional 1,200 shares during the period. Voya Investment Management LLC increased its stake in Aratana Therapeutics by 22.7% during the second quarter. Voya Investment Management LLC now owns 19,530 shares of the biopharmaceutical company’s stock valued at $141,000 after acquiring an additional 3,610 shares during the period. American International Group Inc. increased its stake in Aratana Therapeutics by 7.1% during the first quarter. American International Group Inc. now owns 20,534 shares of the biopharmaceutical company’s stock valued at $109,000 after acquiring an additional 1,354 shares during the period. Ray Gerald L & Associates Ltd. increased its stake in Aratana Therapeutics by 0.8% during the second quarter. Ray Gerald L & Associates Ltd. now owns 24,100 shares of the biopharmaceutical company’s stock valued at $174,000 after acquiring an additional 200 shares during the period. Finally, ProShare Advisors LLC increased its stake in Aratana Therapeutics by 7.2% during the second quarter. ProShare Advisors LLC now owns 25,322 shares of the biopharmaceutical company’s stock valued at $183,000 after acquiring an additional 1,709 shares during the period. Hedge funds and other institutional investors own 73.39% of the company’s stock.
Aratana Therapeutics Company Profile
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.